Imatinib Mesylate Tablet, Film Coated
Product Images NDC 51407-270

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 51407-270). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-269-90lb Imatinib Mesylate 100 mg Tab.jpg (51407 269 90lb Imatinib Mesylate 100 mg Tab)

Label for Imatinib Mesylate tablets, 100 mg strength, containing 90 tablets. The label displays the product name in bold blue text, dosage form as tablets, and quantity. It also includes the NDC 51407-269-90 and indicates Rx only. The labeler shown is Golden State Medical Supply, Inc., with storage instructions and lot, expiration, and serial number fields. Additional regulatory and usage information is present in smaller text.*

FDA Label Image

51407-270-30lb Imatinib Mesylate 100 mg Tab.jpg (51407 270 30lb Imatinib Mesylate 100 mg Tab)

Imatinib Mesylate 400 mg film-coated tablets label for a package containing 30 tablets, manufactured by Golden State Medical Supply, Inc. The label includes storage instructions and a barcode, with the product name prominently displayed in blue and black text. It specifies that the product is prescription only (Rx only).*

FDA Label Image

Imatinib Structural Formula (Image 01)

Chemical structure of imatinib mesylate, the active ingredient in Imatinib Mesylate tablets. The diagram shows the molecular arrangement of atoms including aromatic rings and sulfonate group characteristic of the mesylate salt form.*

FDA Label Image

Figure 1: Progression Free Survival (itt Principle) (Image 04)

A Kaplan-Meier plot showing the percentage of patients without progression over months since randomization comparing Imatinib versus IFN plus Ara-C treatment arms. The chart includes the number of patients at risk and statistical values such as hazard ratio with 95% confidence intervals and the log-rank test p-value.*

FDA Label Image

Figure 2: Time To Progression To Ap Or Bc (itt Principle) (Image 05)

A Kaplan-Meier survival curve comparing the percentage of patients without progression to AP or BC over 72 months since randomization in two treatment arms: Imatinib and IFN+Ara-C. The graph includes patient counts, hazard ratio, confidence interval, and a statistical significance value.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.